On Tuesday, Shares of American Airlines Group Inc (NASDAQ:AAL), gained 2.45% to $42.70.
American Airlines Group, stated July 2015 and year-to-date traffic results.
American Airlines Group’s total revenue passenger miles (RPMs) for the month were a record 21.8 billion, up 4.8 percent as compared to July 2014. Total capacity was a record 24.9 billion accessible seat miles (ASMs), up 2.2 percent as compared to July 2014. Total passenger load factor was 87.3 percent, up 2.2 percentage points as compared to July 2014.
American Airlines Group Inc., through its auxiliaries, operates in the airline industry. As of December 31, 2014, the company operated 983 mainline jets, in addition to 566 regional aircrafts through regional airline auxiliaries and third-party regional carriers. It serves 339 destinations in 54 countries.
Shares of SM Energy Co (NYSE:SM), declined -0.66% to $37.45, during its last trading session.
SM Energy Company declared that the Company will be participating in the following forthcoming investor events:
- August 19, 2015 – Enercom The Oil and Gas Conference. Jay Ottoson, President and CEO, will present at 10:30 AM Mountain Time.
- September 8, 2015 – Barclays CEO Energy-Power Conference. Jay Ottoson, President and CEO, will present at 11:45 AM Eastern Time.
SM Energy Company, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids in onshore North America.
Finally, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), ended its last trade with -7.78% loss, and closed at $4.03.
Catalyst Pharmaceuticals, stated financial results for the second quarter and six months ended June 30, 2015.
Q2 and Recent Highlights:
- Development and advancement of comprehensive commercialization and pre-launch plan
- Presented at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA
- Declared top-line results in proof-of-concept trial of Vigabatrin in patients with treatment-refractory Tourette’s Disorder
- Joined Russell 2000®, 3000® and Global Indexes
- Designated Dr. Gary Ingenito as Chief Medical Officer
- Initiated rolling NDA submission for Firdapse® for the treatment of LEMS.
Catalyst Pharmaceuticals, Inc., a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
